27 research outputs found
Transition path to a dense efficient-packed post-delafossite phase. Crystal structure and evolution of the chemical bonding
[EN] A(I)B(III)O(2) delafossite-type oxides are important technological compounds characterized by the linear coordination of the monovalent A metal by oxygen atoms. Based on results of in situ synchrotron X-ray diffraction measurements and ab initio calculations, we herein report on the high-pressure behavior of AgGaO2, to the best of our knowledge the first compound showing step-wise transitions of Ag coordination from linear (2) to octahedral (6), through a leaning delafossite structure. These transformations take place at similar to 10.5 and similar to 16.5 GPa, respectively. Our structural analysis evidences that the initial rhombohedral delafossite structure first becomes dynamically unstable, and distorts continuously via a gliding motion of the [GaO2] octahedral layers within the ab plane, and subsequently transform into another rhombohedral phase 8% denser. This structural sequence is associated with a simultaneous decrease in the bond order of the Ag-O bonds and an increase in the ionicity of the crystal. These results may help to unveil the high-pressure phases of several delafossite compounds which were reported to undergo phase transitions under compression that could not be identified.We are thankful for the financial support received from the Spanish Ministerio de Ciencia e Innovacion and the Agencia Estatal de Investigacion under national projects PGC2018-094417-B-I00 (co-financed by EU FEDER funds), MAT2016-75586-C4-1-P/2-P, FIS2017-83295-P, PID2019-106383GB-C41/C42 and RED2018-102612-T (MALTA Consolider), and from Generalitat Valenciana under project PROMETEO/2018/123. D.S-P, A.O.R, and J.A.S acknowledge financial support of the Spanish MINECO for the RyC-2014-15643, RyC-2016-20301, and RyC-2015-17482 Ramon y Cajal Grants, respectively. Authors thank ALBA-CELLS synchrotron for providing beamtime (ALBA experiments 2012010170).Chuliá-Jordán, R.; Santamaria-Perez, D.; Pellicer-Porres, J.; Otero-De-La-Roza, A.; Martinez-Garcia, D.; García-Domene, B.; Gomis, O.... (2021). Transition path to a dense efficient-packed post-delafossite phase. Crystal structure and evolution of the chemical bonding. Journal of Alloys and Compounds. 867. https://doi.org/10.1016/j.jallcom.2021.15901215901286
Noncommutative quantum mechanics and Bohm's ontological interpretation
We carry out an investigation into the possibility of developing a Bohmian
interpretation based on the continuous motion of point particles for
noncommutative quantum mechanics. The conditions for such an interpretation to
be consistent are determined, and the implications of its adoption for
noncommutativity are discussed. A Bohmian analysis of the noncommutative
harmonic oscillator is carried out in detail. By studying the particle motion
in the oscillator orbits, we show that small-scale physics can have influence
at large scales, something similar to the IR-UV mixing
Gluon polarization in the nucleon from quasi-real photoproduction of high-pT hadron pairs
We present a determination of the gluon polarization Delta G/G in the
nucleon, based on the helicity asymmetry of quasi-real photoproduction events,
Q^2<1(GeV/c)^2, with a pair of large transverse-momentum hadrons in the final
state. The data were obtained by the COMPASS experiment at CERN using a 160 GeV
polarized muon beam scattered on a polarized 6-LiD target. The helicity
asymmetry for the selected events is = 0.002 +- 0.019(stat.) +-
0.003(syst.). From this value, we obtain in a leading-order QCD analysis Delta
G/G=0.024 +- 0.089(stat.) +- 0.057(syst.) at x_g = 0.095 and mu^2 =~ 3
(GeV}/c)^2.Comment: 10 pages, 3 figure
Measurement of the Spin Structure of the Deuteron in the DIS Region
We present a new measurement of the longitudinal spin asymmetry A_1^d and the
spin-dependent structure function g_1^d of the deuteron in the range 1 GeV^2 <
Q^2 < 100 GeV^2 and 0.004< x <0.7. The data were obtained by the COMPASS
experiment at CERN using a 160 GeV polarised muon beam and a large polarised
6-LiD target. The results are in agreement with those from previous experiments
and improve considerably the statistical accuracy in the region 0.004 < x <
0.03.Comment: 10 pages, 6 figures, subm. to PLB, revised: author list, Fig. 4,
details adde
The COMPASS Experiment at CERN
The COMPASS experiment makes use of the CERN SPS high-intensitymuon and
hadron beams for the investigation of the nucleon spin structure and the
spectroscopy of hadrons. One or more outgoing particles are detected in
coincidence with the incoming muon or hadron. A large polarized target inside a
superconducting solenoid is used for the measurements with the muon beam.
Outgoing particles are detected by a two-stage, large angle and large momentum
range spectrometer. The setup is built using several types of tracking
detectors, according to the expected incident rate, required space resolution
and the solid angle to be covered. Particle identification is achieved using a
RICH counter and both hadron and electromagnetic calorimeters. The setup has
been successfully operated from 2002 onwards using a muon beam. Data with a
hadron beam were also collected in 2004. This article describes the main
features and performances of the spectrometer in 2004; a short summary of the
2006 upgrade is also given.Comment: 84 papes, 74 figure
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1
High-risk mutations in several genes predispose to both colorectal cancer (CRC) and endometrial cancer (EC). We therefore hypothesised that some lower-risk genetic variants might also predispose to both CRC and EC. Using CRC and EC genome-wide association series, totalling 13,265 cancer cases and 40,245 controls, we found that the protective allele [G] at one previously-identified CRC polymorphism, rs2736100 near TERT, was associated with EC risk (odds ratio (OR) = 1.08, P = 0.000167); this polymorphism influences the risk of several other cancers. A further CRC polymorphism near TERC also showed evidence of association with EC (OR = 0.92; P = 0.03). Overall, however, there was no good evidence that the set of CRC polymorphisms was associated with EC risk, and neither of two previously-reported EC polymorphisms was associated with CRC risk. A combined analysis revealed one genome-wide significant polymorphism, rs3184504, on chromosome 12q24 (OR = 1.10, P = 7.23 × 10−9) with shared effects on CRC and EC risk. This polymorphism, a missense variant in the gene SH2B3, is also associated with haematological and autoimmune disorders, suggesting that it influences cancer risk through the immune response. Another polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, P = 4.82 × 10−8), with the alleles showing opposite effects on the risks of the two cancers
RICORS2040 : The need for collaborative research in chronic kidney disease
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
Aims The aim of this study was to develop, validate, and illustrate an updated prediction model (SCORE2) to estimate 10-year fatal and non-fatal cardiovascular disease (CVD) risk in individuals without previous CVD or diabetes aged 40-69 years in Europe.Methods and results We derived risk prediction models using individual-participant data from 45 cohorts in 13 countries (677 684 individuals, 30 121 CVD events). We used sex-specific and competing risk-adjusted models, including age, smoking status, systolic blood pressure, and total- and HDL-cholesterol. We defined four risk regions in Europe according to country-specific CVD mortality, recalibrating models to each region using expected incidences and risk factor distributions. Region-specific incidence was estimated using CVD mortality and incidence data on 10 776 466 individuals. For external validation, we analysed data from 25 additional cohorts in 15 European countries (1 133 181 individuals, 43 492 CVD events). After applying the derived risk prediction models to external validation cohorts, C-indices ranged from 0.67 (0.65-0.68) to 0.81 (0.76-0.86). Predicted CVD risk varied several-fold across European regions. For example, the estimated 10-year CVD risk for a 50-year-old smoker, with a systolic blood pressure of 140 mmHg, total cholesterol of 5.5 mmol/L, and HDL-cholesterol of 1.3 mmol/L, ranged from 5.9% for men in low- risk countries to 14.0% for men in very high-risk countries, and from 4.2% for women in low-risk countries to 13.7% for women in very high-risk countries.Conclusion SCORE2-a new algorithm derived, calibrated, and validated to predict 10-year risk of first-onset CVD in European populations-enhances the identification of individuals at higher risk of developing CVD across Europe.Cardiolog
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.
GWAS have identified >200 risk loci for Inflammatory Bowel Disease (IBD). The majority of disease associations are known to be driven by regulatory variants. To identify the putative causative genes that are perturbed by these variants, we generate a large transcriptome data set (nine disease-relevant cell types) and identify 23,650 cis-eQTL. We show that these are determined by ∼9720 regulatory modules, of which ∼3000 operate in multiple tissues and ∼970 on multiple genes. We identify regulatory modules that drive the disease association for 63 of the 200 risk loci, and show that these are enriched in multigenic modules. Based on these analyses, we resequence 45 of the corresponding 100 candidate genes in 6600 Crohn disease (CD) cases and 5500 controls, and show with burden tests that they include likely causative genes. Our analyses indicate that ≥10-fold larger sample sizes will be required to demonstrate the causality of individual genes using this approach
Repositioning of the global epicentre of non-optimal cholesterol
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.</p